Found 2,842 articles
Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2022
Poolbeg Pharma Plc a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, is pleased to announce its audited results for the year ended 31 December 2022.
Astellas and Roche Diabetes Care Japan ink partnership agreement to develop and commercialize integrated diabetes self-management solution with BlueStar®
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that it has entered into an agreement ("the Agreement") with Roche Diabetes Care Japan Co., Ltd. (Country Manager: Noriko Hattori, "Roche Diabetes Care Japan") for the development and commercialization of Roche Diabetes Care's world-renowned Accu-Chek® Guide Me blood glucose monitoring system with advanced accuracy as a combined medical product with BlueStar.
BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
BioNTech SE reported financial results for the three months and full year ended December 31, 2022, and provided an update on its corporate progress.
COLUMVI® (Glofitamab for Injection) Receives Health Canada Authorization with Conditions for Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Hoffmann-La Roche Limited announced that on March 24, 2023 Health Canada authorized COLUMVI® for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, DLBCL arising from follicular lymphoma, or primary mediastinal B-cell lymphoma, who have received two or more lines of systemic therapy and are ineligible to receive or cannot receive CAR-T cell therapy or have previously received CAR-T cell therapy.
Ferring Announces Abstract of the First Prospective, Multi-National, Real-world Study of Rekovelle® (follitropin delta) at the Congress of the Pacific Society for Reproductive Medicine
An oral poster of the first post-authorisation Phase 4 real-world study, PROFILE, is being presented at the 13th Congress of the Pacific Society for Reproductive Medicine 2023 in Australia.
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Lineage Cell Therapeutics, Inc. today reported financial and operating results for the fourth quarter and full year ended December 31, 2022 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results.
FDA Advisory Committee Votes in Favor of the Clinical Benefit of Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 11 to 2 in favor of Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL).
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022.
Alpha-9 Theranostics Strengthens its Scientific Expertise with Key Appointments to Leadership Team and Scientific Advisory Board
Alpha-9 Theranostics, a clinical stage biotechnology company developing differentiated and highly targeted radiopharmaceuticals, announced the appointment of Jutta Wanner, Ph.D. as Senior Vice President of Drug Discovery.
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023
Lineage Cell Therapeutics, Inc. today announced that it will report its fourth quarter and full year 2022 financial and operating results on Thursday, March 9, 2023, following the close of the U.S. financial markets.
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022.
Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the fourth quarter and full year 2022.
Seagen Reports Fourth Quarter and Full Year 2022 Financial Results
Seagen Inc. (Nasdaq:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2022.
Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer
Silence Therapeutics plc today announced the appointment of J.P. Gabriel as Chief Technical Operations Officer following the retirement of Jørgen Wittendorff, SVP, Technical Operations.
Repare Therapeutics Receives $1.5 Million (¥200 million) Payment from Ono Pharmaceuticals
Repare Therapeutics Inc. today announced that the Company has received an approximately $1.5 million (¥200 million) research service payment from Ono Pharmaceutical Co., Ltd. (“Ono”).
Angle PLC Announces Appointment of Non-Executive Director
ANGLE plc, a world-leading liquid biopsy company, is delighted to announce that Joseph Eid M.D. has been appointed as a Non-Executive Director of the Company, with effect from 19 January 2023.
Belharra Therapeutics Debuts With $130 Million in Funding
Belharra Therapeutics, Inc. today emerged from stealth mode with a novel photoaffinity-based chemoproteomics platform capable of identifying non-covalent, small molecule drug candidates for any protein.
Point-of-Care Testing (POCT) Market Size To Attain USD 103.2 Bn By 2030
The global point-of-care testing (POCT) market size accounted for USD 45.03 billion in 2022 and is expected to attain around USD 103.2 billion by 2030 with a noteworthy CAGR of 10.92% from 2022 to 2030.
Molecular Diagnostics Market Size Is Expanding USD 48.9 Billion By 2030
The global molecular diagnostics market size accounted for USD 14.75 bn in 2022 and is expanding around USD 48.9 billion by 2030 with a registered CAGR 16.16% from 2022 to 2030.
Cell and Gene Therapy Market Size To Expand USD 93.78 Bn By 2030
The global cell and gene therapy market size was exhibited at USD 18.61 billion in 2022 and is expected to expand around USD 93.78 billion by 2030, poised to grow at a projected CAGR of 22.41% from 2022 to 2030.